Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Razvoj novih sistemskih zdravljenj pri bolnikih z razsejanim rakom prostate
Authors:Šeruga, Boštjan (Author)
Milanez, Tomaž (Author)
Borštnar, Simona (Author)
Snoj Šarvari, Nataša (Author)
Škrbinc, Breda (Author)
Language:Slovenian
Tipology:1.04 - Professional Article
Organisation:Logo OI - Institute of Oncology
Abstract:Hormonsko zdravljenje s kastracijo je v začetku navadno učinkovito pri večini bolnikov z razsejanim rakom prostate, vendar bolezen čez čas neizbežno napreduje. Docetaksel v kombinaciji s prednizonom predstavlja standardno zdravljenje v prvi liniji zdravljenja bolnikov z razsejanim, proti kastraciji odpornim rakom prostate (rKORP). Do danes je bilo v kliničnih raziskavah preizkušenih več učinkovin v kombinaciji z docetakselom, vendar se nobena kombinacija ni izkazala za učinkovitejšo od docetaksela samega. Za bolnike z rKORP, pri katerih bolezen napreduje po zdravljenju z docetakselom, predstavljata kabazitaksel in abirateron acetat novi možnosti sistemskega zdravljenja.
Keywords:prostata, rak (medicina), zdravljenje
Year of publishing:2011
COBISS_ID:1196667 Link is opened in a new window
UDC:616.6-006.6-085
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
URN:URN:NBN:SI:doc-LBUPBLVQ
Note:Soavtorji: T. Milanez, S. Borštnar, N. Snoj, B. Škrbinc;
Views:2143
Downloads:558
Files:.pdf PDF - Presentation file, download (157,10 KB)
 
Journal:Onkologija
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Clinical development of new systemic therapies in patients with metastatic prostate cancer
Abstract:Hormonal therapy with castration is initially effective in the majority of men with metastatic prostate cancer, but the disease invariably progresses. Docetaxel in combination with prednisone is the standard first-line treatment in men with metatstatic castration-resistant prostate cancer (mCRPC). Although several experimental agents have been evaluated in combination with docetaxel to date, none of these combinations improved the efficacy of docetaxel. Cabazitaxel and abirateron acetate are new options for systemic treatment in men with mCRPC who have progressive disease after treatment with docetaxel.

Archive

niGradiv

Back